Geographical Expansion
Expected: FY26HIGH confidence
What: New markets entered: 3 countries
Impact: 15% revenue growth
Bliss GVS Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +48.5%Weak12w Streak
In , Bliss GVS Pharma Ltd (Pharma - Formulators) is outperforming Nifty 500 with +48.5% relative strength. Fundamentals: Weak. On a 12-week streak.
Bliss GVS Pharma Ltd Key Facts
- PE Ratio
- 25.8x
- Price/Book
- 1.71x
- Market Cap
- ₹2,853 Cr
- PAT Growth YoY
- -4%
- Revenue Growth YoY
- +4%
- OPM
- 16.0%
- RS vs Nifty 500
- +48.5%
PE: At PeakRiding Wave
What's Happening
📊PE near cycle highs — limited room for further expansion
💪Debt reduced 41% YoY — balance sheet strengthening
👔Promoter buying — stake up 0.6% this quarter
🌐FII stake increased 1.1% this quarter
💰Trading 6% above estimated fair value
Earnings Acceleration Triggers
1. Geographical Expansion
FY26HIGH
2. Value Added Product Mix Shift
FY26MEDIUM
Key Risks
1. Exposure to currency fluctuations in African markets, particularly the Nigerian
MEDIUM2. Ongoing compliance requirements for WHO-GMP and local health authority audits in
LOWSector-Specific Signals
Africa Revenue Share78%-200 bps
R&D as % of Sales3.2%+40 bps
Suppository Revenue Contribution22%+300 bps
Key Numbers
PAT Growth YoY
-4%
Inflection Down
Revenue YoY
+4%
Stable
Operating Margin
16.0%
+200 bps YoY
PE Ratio
25.8
PEG Ratio
1.89
EV/EBITDA
14.7
Current Price
₹270
Dividend Yield
0.19%
Fundamental Score
31/100
Weak
3Y PAT CAGR
+58%
Market Cap
2.9K Cr
Valuation
Fairly Valued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Bliss GVS Pharma Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 18, 2026
Value Added Product Mix Shift
Expected: FY26MEDIUM confidence
What: Suppository sales share: 22%
Impact: 150 bps margin expansion
What Are the Key Risks for Bliss GVS Pharma Ltd?
Earnings deceleration risks from management commentary
Exposure to currency fluctuations in African markets, particularly the Nigerian
MEDIUMTrigger: Exposure to currency fluctuations in African markets, particularly the Nigerian Naira and Kenyan Shilling.
Impact: PAT impact: 5-7%
Management view: Natural hedging and forward contracts
Monitor: fx
Ongoing compliance requirements for WHO-GMP and local health authority audits in
LOWTrigger: Ongoing compliance requirements for WHO-GMP and local health authority audits in export markets.
Impact: PAT impact: null
Management view: Continuous quality audits
Monitor: regulatory
What Did Bliss GVS Pharma Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
INR 232.07 Cr
YoY +10.9%QoQ +13.5%
Revenue growth was driven by expansion in the African market and increased sales of anti-malarial formulations.
EBITDA
INR 41.77 Cr
YoY +15.2%Margin 18%
EBITDA margins expanded due to lower raw material costs and higher contribution from value-added products.
PAT
INR 24.50 Cr
YoY +22.5%QoQ +18.2%
PAT growth outpaced revenue growth due to interest cost reduction and tax optimization.
Other Highlights
• Gross debt reduced by INR 15 Cr
• African market contributed 78% of revenue
• R&D spend at 3.2% of sales
What Sector Metrics Matter for Bliss GVS Pharma Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Africa Revenue Share
78%
YoY -200 bpsQoQ null
Why: Strategic diversification into other emerging markets like Southeast Asia.
R&D as % of Sales
3.2%
YoY +40 bpsQoQ null
Why: Increased investment in developing complex suppository formulations.
Suppository Revenue Contribution
22%
YoY +300 bpsQoQ null
Why: Higher uptake of specialized dosage forms in export markets.
What Is Bliss GVS Pharma Ltd's Management Guidance?
Forward-looking targets from management for FY26
Revenue Growth Target
13.5%
OPM Guidance
19.5%
Capex Plan
₹45 Cr
Revenue Outlook
12-15%
Margin Outlook
Margin expansion expected
Capex Plan
INR 45 Cr
Capacity expansion at Palghar plant
Management Tone: BULLISH
How Fast Is Bliss GVS Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +4% | +3% | Stable |
| PAT (Net Profit) | -4% | +58% | Inflection Down |
| OPM | 16.0% | +200 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Bliss GVS Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Bliss GVS Pharma Ltd's latest quarterly results?
Bliss GVS Pharma Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -3.8% (inflecting downward)
- Revenue Growth YoY: +3.8%
- Operating Margin: 16.0% (stable)
Is Bliss GVS Pharma Ltd's profit growing or declining?
Bliss GVS Pharma Ltd's profit is declining with an inflecting downward trend.
- PAT Growth YoY: -3.8% (latest quarter)
- PAT Growth QoQ: -13.8% (sequential)
- 3-Year PAT CAGR: +57.6%
- Trend: Inflecting downward — consistent growth pattern
What is Bliss GVS Pharma Ltd's revenue growth trend?
Bliss GVS Pharma Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +3.8%
- Revenue Growth QoQ: -10.7% (sequential)
- 3-Year Revenue CAGR: +2.7%
How is Bliss GVS Pharma Ltd's operating margin trending?
Bliss GVS Pharma Ltd's operating margin is stable.
- Current OPM: 16.0%
- OPM Change YoY: +2.0% basis points
- OPM Change QoQ: -2.0% basis points
What is Bliss GVS Pharma Ltd's 3-year profit and revenue CAGR?
Bliss GVS Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +57.6%
- 3-Year Revenue CAGR: +2.7%
Is Bliss GVS Pharma Ltd's growth accelerating or decelerating?
Bliss GVS Pharma Ltd's earnings growth is inflecting downward with mixed signals on a sequential basis.
- YoY Acceleration: -15.3% bps
- Sequential Acceleration: +20.3% bps
What is Bliss GVS Pharma Ltd's trailing twelve month (TTM) performance?
Bliss GVS Pharma Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹115 Cr
- TTM PAT Growth: +66.7% YoY
- TTM Revenue: ₹867 Cr
- TTM Revenue Growth: +7.0% YoY
- TTM Operating Margin: 16.4%
Is Bliss GVS Pharma Ltd overvalued or undervalued?
Bliss GVS Pharma Ltd appears fairly valued based on our fair value analysis.
- Valuation Signal: Fairly Valued
- Current PE: 25.8x
- Price-to-Book: 2.5x
What is Bliss GVS Pharma Ltd's current PE ratio?
Bliss GVS Pharma Ltd's current PE ratio is 25.8x.
- Current PE: 25.8x
- Market Cap: 2.9K Cr
- Dividend Yield: 0.19%
How does Bliss GVS Pharma Ltd's valuation compare to its history?
Bliss GVS Pharma Ltd's current PE is 25.8x.
- Current PE: 25.8x
- Valuation Assessment: Fairly Valued
What is Bliss GVS Pharma Ltd's price-to-book ratio?
Bliss GVS Pharma Ltd's price-to-book ratio is 2.5x.
- Price-to-Book (P/B): 2.5x
- Book Value per Share: ₹107
- Current Price: ₹270
Is Bliss GVS Pharma Ltd a fundamentally strong company?
Bliss GVS Pharma Ltd is rated Weak with a fundamental score of 31.46/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +3.8% (10% weight)
- PAT Growth YoY: -3.8% (10% weight)
- PAT Growth QoQ: -13.8% (10% weight)
- Margins stable (10% weight)
- PEG Ratio: 1.9x vs sector median (15% weight)
- EV/EBITDA: 14.7x vs sector median (15% weight)
Is Bliss GVS Pharma Ltd debt free?
Bliss GVS Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹52 Cr
What is Bliss GVS Pharma Ltd's return on equity (ROE) and ROCE?
Bliss GVS Pharma Ltd's return ratios over recent years
- FY2023: ROCE 12.0%
- FY2024: ROCE 14.0%
- FY2025: ROCE 12.0%
Is Bliss GVS Pharma Ltd's cash flow positive?
Bliss GVS Pharma Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹106 Cr
- Free Cash Flow (FCF): ₹31 Cr
- CFO/PAT Ratio: 118% (strong cash conversion)
What is Bliss GVS Pharma Ltd's dividend yield?
Bliss GVS Pharma Ltd's current dividend yield is 0.19%.
- Dividend Yield: 0.19%
- Current Price: ₹270
Who holds Bliss GVS Pharma Ltd shares — promoters, FII, DII?
Bliss GVS Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 35.4%
- FII (Foreign): 10.4%
- DII (Domestic): 5.0%
- Public: 49.1%
Is promoter holding increasing or decreasing in Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 35.4% (Mar 2026)
- Previous Quarter: 35.4% (Dec 2025)
- Change: 0.00% (stable)
How long has Bliss GVS Pharma Ltd been outperforming Nifty 500?
Bliss GVS Pharma Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Is Bliss GVS Pharma Ltd a new momentum entry or an established outperformer?
Bliss GVS Pharma Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has 2 key growth catalysts identified from recent earnings analysis
- Geographical Expansion — New markets provide a significant runway for volume growth in under-penetrated regions.
- Value Added Product Mix Shift — Shift toward specialized dosage forms improves pricing power and reduces competition.
What are the key risks in Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has 2 key risks worth monitoring
- [MEDIUM] Exposure to currency fluctuations in African markets, particularly the Nigerian — Exposure to currency fluctuations in African markets, particularly the Nigerian Naira and Kenyan Shilling.
- [LOW] Ongoing compliance requirements for WHO-GMP and local health authority audits in — Ongoing compliance requirements for WHO-GMP and local health authority audits in export markets.
What is Bliss GVS Pharma Ltd's management guidance for growth?
Bliss GVS Pharma Ltd's management has provided the following forward guidance for FY26
- Revenue growth target: 13.5%
- OPM guidance: 19.5%
- Capex plan: ₹45 Cr for Capacity expansion at Palghar plant
- Management tone: bullish
What sector-specific metrics matter most for Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd's most important sub-sector-specific KPIs from the latest concall
- Africa Revenue Share: 78% (YoY -200 bps) (QoQ null) — Strategic diversification into other emerging markets like Southeast Asia.
- R&D as % of Sales: 3.2% (YoY +40 bps) (QoQ null) — Increased investment in developing complex suppository formulations.
- Suppository Revenue Contribution: 22% (YoY +300 bps) (QoQ null) — Higher uptake of specialized dosage forms in export markets.
Is Bliss GVS Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Bliss GVS Pharma Ltd may be worth studying
- Cash flow is positive — CFO ₹106 Cr
What is the investment thesis for Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Geographical Expansion
Risk Factors (Bear Case)
- Key risk: Exposure to currency fluctuations in African markets, particularly the Nigerian
What is the future outlook for Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: inflecting downward
- Revenue Trend: stable
- Margin Trend: stable
- Valuation: Fairly Valued
- Key Catalyst: Geographical Expansion
- Key Risk: Exposure to currency fluctuations in African markets, particularly the Nigerian
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.